drugset / Trial / NCT01013831
Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung
NaSingle-groupOpen-labelPrevention
Summary
This phase I trial studies the side effects and best dose of erlotinib hydrochloride in preventing cancer in patients with precancerous lesions of the lung. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2009-10
- Primary completion
- 2012-02
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 25 mg | Oral |
| Subject | Erlotinib | Small molecule | 50 mg | Oral |
| Subject | Erlotinib | Small molecule | 75 mg | Oral |
| Subject | Erlotinib | Small molecule | 100 mg | Oral |